← 返回

释放川芎嗪的水凝胶通过重编程肿瘤血管增强 CAR-T 细胞治疗三阴性乳腺癌的疗效

英文原题:A tetramethylpyrazine releasing hydrogel can potentiate CAR-T cell therapy against triple negative breast cancer by reprogramming tumor vasculatures.

查看英文原题

A tetramethylpyrazine releasing hydrogel can potentiate CAR-T cell therapy against triple negative breast cancer by reprogramming tumor vasculatures.

PubMed 2023/06/19(内容时间) Fundam Res Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

实体瘤的不规则血管系统已被证明是限制其应答CAR-T(CAR-T)细胞疗法的关键因素,因为其与缺氧及其他生物屏障密切相关。

在此,我们开发了一种由聚乙二醇二甲基丙烯酸酯(PEGDMA)和氯化亚铁(FeCl2)组成的可注射水凝胶,该水凝胶可响应内源性过氧化氢(H2O2),实现中药提取物川芎嗪(TMP)在瘤内的持续释放。选择TMP是因为其能有效激活血管内皮细胞中血管内皮生长因子(VEGF)的表达以及内皮型一氧化氮合酶/一氧化氮(eNOS/NO)轴。当TMP被固定于基于PEGDMA的水凝胶中并置于肿瘤内后,TMP可通过同时促进血管生成和扩张肿瘤血管来重塑肿瘤血管系统,从而在两种携带人三阴性乳腺癌(TNBC)的小鼠异种移植瘤中减轻肿瘤缺氧。结果,TMP固定治疗通过促进肿瘤浸润、存活和效应功能,增强了静脉注射表达表皮生长因子受体的CAR-T(HER1-CAR-T)细胞对两种TNBC肿瘤异种移植瘤的肿瘤抑制效果。

本研究强调了一种简洁而有效的方法,即通过简单地重塑肿瘤血管系统来增强CAR-T 细胞对靶向实体瘤的治疗效力。

展开英文摘要原文

Irregular vasculature of solid tumors has proven to be a pivotal factor restricting their response to chimeric antigen receptor-T (CAR-T) cell therapy because it is tightly associated with hypoxia and other biological barriers.

Herein, an injectable hydrogel composed of poly (ethylene glycol) dimethacrylate (PEGDMA) and ferrous chloride (FeCl 2 ) responding to endogenous hydrogen peroxides (H 2 O 2 ) is developed to enable sustained intratumoral release of Chinese herbal extracts tetramethylpyrazine (TMP). TMP is selected due to its potency in activating vascular endothelial growth factor (VEGF) expression and the endothelial nitric oxide synthase/nitric oxide (eNOS/NO) axis inside vascular endothelial cells.

Upon being fixed inside tumors with the PEGDMA based hydrogel, TMP can remodel tumor vasculature by simultaneously promoting angiogenesis and dilating tumor vasculature and thus attenuate tumor hypoxia in two murine xenografts bearing human triple negative breast cancer (TNBC).

Resultantly, treatment with TMP fixation potentiates the tumor suppression effect of intravenously injected epidermal growth factor receptor expressing CAR-T (HER1-CAR-T) cells toward two TNBC tumor xenografts by promoting their tumor infiltration, survival, and effector function.

This study highlights a concise yet effective approach to reinforce the therapeutic potency of CAR-T cells towards targeted solid tumors by simply remodeling tumor vasculature.

论文信息

作者
Liu Y、Hao Y、Lv X、Zhang Y、Chen J、Tian J、Ma X、Zhou Y
第一作者单位
Jiangsu Key Laboratory for Molecular and Medical Biotechnology, Cancer Institute, Department of Biochemistry, College of Life Science, Nanjing Normal University, Nanjing 210023, China.China
通讯作者单位
Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou 215123, China.China
期刊
Fundamental research2025 May
原文标识
PubMed 40528964 · DOI 10.1016/j.fmre.2023.05.016